SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Shares Purchased by Opus Capital Group LLC

Opus Capital Group LLC grew its position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 291.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 135,000 shares of the company’s stock after acquiring an additional 100,500 shares during the quarter. Opus Capital Group LLC’s holdings in SELLAS Life Sciences Group were worth $143,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SLS. Geode Capital Management LLC boosted its position in SELLAS Life Sciences Group by 30.0% during the 4th quarter. Geode Capital Management LLC now owns 188,066 shares of the company’s stock worth $443,000 after purchasing an additional 43,347 shares during the period. State Street Corp lifted its stake in shares of SELLAS Life Sciences Group by 36.7% during the first quarter. State Street Corp now owns 51,236 shares of the company’s stock worth $342,000 after purchasing an additional 13,768 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in shares of SELLAS Life Sciences Group in the first quarter valued at about $208,000. Equitable Holdings Inc. raised its holdings in shares of SELLAS Life Sciences Group by 15.0% during the 1st quarter. Equitable Holdings Inc. now owns 130,000 shares of the company’s stock valued at $186,000 after buying an additional 17,000 shares during the period. Finally, Millennium Management LLC lifted its position in SELLAS Life Sciences Group by 146.9% during the 4th quarter. Millennium Management LLC now owns 61,179 shares of the company’s stock worth $144,000 after acquiring an additional 36,396 shares in the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Trading Up 3.7 %

NASDAQ:SLS traded up $0.05 during trading hours on Wednesday, hitting $1.41. The stock had a trading volume of 560,811 shares, compared to its average volume of 1,456,324. The company has a market cap of $79.34 million, a PE ratio of -1.03 and a beta of 2.35. The business has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $0.99. SELLAS Life Sciences Group, Inc. has a 1-year low of $0.50 and a 1-year high of $1.91.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.